Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of EXG202 injection in wet age-related macular degeneration
CTR20253757Phase 2Active
- Sponsor
- Hangzhou RebornGene Therapeutics Co., Ltd.
- Start
- Sep 2025
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of EXG202 in exudative macular degeneration, sponsored by Hangzhou RebornGene Therapeutics Co., Ltd.. Started Sep 2025; status: active.
02
Drugs
EXG202
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20253757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253757.